[HTML][HTML] Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007
…, JO Velez, AJ Lambert, AJ Johnson… - Emerging infectious …, 2008 - ncbi.nlm.nih.gov
Zika virus (ZIKV) is a mosquito-borne flavivirus first isolated in Uganda from a sentinel monkey
in 1947. Mosquito and sentinel animal surveillance studies have demonstrated that ZIKV …
in 1947. Mosquito and sentinel animal surveillance studies have demonstrated that ZIKV …
[HTML][HTML] Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
…, W Zhao, NA Heerema, AJ Johnson… - … England Journal of …, 2013 - Mass Medical Soc
Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in
few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell–…
few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell–…
[HTML][HTML] Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
…, JJ Buggy, BY Chang, AJ Johnson… - … England Journal of …, 2014 - Mass Medical Soc
Background Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is
effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and …
effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and …
[HTML][HTML] Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia
…, R Izumi, TG Diacovo, AJ Johnson… - … England Journal of …, 2016 - Mass Medical Soc
Background Irreversible inhibition of Bruton’s tyrosine kinase (BTK) by ibrutinib represents
an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). …
an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). …
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
… Most of these individuals had received two doses of mRNA vaccination, with three individuals
receiving the third booster and one having the Johnson & Johnson vaccine. The vaccine …
receiving the third booster and one having the Johnson & Johnson vaccine. The vaccine …
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
…, JJ Buggy, A Hamdy, AJ Johnson… - Blood, The Journal …, 2011 - ashpublications.org
B-cell receptor (BCR) signaling is aberrantly activated in chronic lymphocytic leukemia (CLL).
Bruton tyrosine kinase (BTK) is essential to BCR signaling and in knockout mouse models …
Bruton tyrosine kinase (BTK) is essential to BCR signaling and in knockout mouse models …
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular …
Targeted therapy with imatinib in chronic myeloid leukemia (CML) prompted a new treatment
paradigm. Unlike CML, chronic lymphocytic leukemia (CLL) lacks an aberrant fusion …
paradigm. Unlike CML, chronic lymphocytic leukemia (CLL) lacks an aberrant fusion …
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
…, A Kashishian, B Steiner, AJ Johnson… - Blood, The Journal …, 2011 - ashpublications.org
Phosphatidylinositol-3-kinase p110δ serves as a central integration point for signaling from
cell surface receptors known to promote malignant B-cell proliferation and survival. This …
cell surface receptors known to promote malignant B-cell proliferation and survival. This …
Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey
…, AD Fine, MC Layton, SM Mullin, AJ Johnson… - The lancet, 2001 - thelancet.com
Background In the summer of 1999, West Nile virus was recognised in the western
hemisphere for the first time when it caused an epidemic of encephalitis and meningitis in the …
hemisphere for the first time when it caused an epidemic of encephalitis and meningitis in the …
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
…, W Zhao, NA Heerema, AJ Johnson… - Blood, The Journal …, 2015 - ashpublications.org
Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell
receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib …
receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib …